Navigation Links
Chemo-radiation before prostate removal may prevent cancer recurrence
Date:11/4/2009

PORTLAND, Ore. Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

Their findings were presented this week at the 51st annual meeting of the American Society of Therapeutic Radiology and Oncology in Chicago.

"In men with aggressive prostate cancer, standard therapies such as radiation or surgery often fail to eliminate the cancer completely at the site of treatment. When these cancers recur, they are often fatal," said Mark Garzotto, M.D., principal investigator and Associate Professor of Urology and Radiation Medicine in the OHSU Knight Cancer Institute; and Chief of Urologic Oncology in the Portland Veterans Affairs Medical Center.

Previous clinical trials examining the effect of either hormonal therapy or chemotherapy prior to surgery have shown little if any benefit over prostate removal alone. "Novel approaches are needed if we are to make advances in this disease," added Dr. Garzotto.

The use of multimodality therapy combined radiation, chemotherapy and surgery has resulted in improved outcomes in a number of cancers, but has not yet been studied in prostate cancer.

This study looked at whether radiation therapy and chemotherapy (docetaxel) administered before surgery is possible, safe, and, ultimately, capable of preventing cancer recurrences. To answer these questions, Garzotto and colleagues developed a treatment regimen in which radiation and docetaxel were administered together before prostatectomy.

Twelve eligible participants were enrolled in the study between April 2006 and March 2008. The men were given intensity-modulated radiation therapy and increasing doses of docetaxel for five consecutive weeks, which was followed by surgical removal of the prostate gland.

The participants tolerated the treatment well and were able to undergo surgery without any major complications, which was a potential concern in this trial. Specifically there were no rectal or ureteral injuries or blood clots in the legs. Examination of the tumor tissue after surgery showed the cancer margins, evidence of complete removal of all of the cancer, to be clean in 75 percent of patients, which is higher than was expected. Also, the PSA, or prostate-specific antigen levels, a predictor of prostate cancer recurrence, were undetectable after treatment in all patients.

"Our study is the first-ever clinical trial in prostate cancer to combine radiation, chemotherapy and surgery given as a combination treatment before prostate surgery to potentially provide higher cure rates than traditional approaches with fewer side effects," said Arthur Hung, M.D., co-investigator and Assistant Professor of Radiation Medicine in the OHSU Knight Cancer Institute.

The researchers concluded this chemo-radiation combination is feasible and safe and potentially may reduce cancer recurrence rates in this high-risk population. Further, they say the development of this approach now opens the door to the study other drugs in combination with radiation.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Heart Test Deemed OK Before Kidney Transplant
2. Video: New Clinical Trial Results Show Germ-Killing Action of LISTERINE(R) Antiseptic Kills Germs in the Mouth Before They Travel to the Bloodstream
3. Sorafenib significantly improves the length of time before breast cancer worsens
4. DARPA awards Duke $19.5 million to detect viral infection before symptoms appear
5. realbuzz.com Top 25 Things to do Before You Die
6. It pays to quit smoking before surgery
7. Statins Before Vascular Surgery Cut Deaths, Complications
8. Abbott Testifies Before U.S. Congress on Role of Private Sector in Advancing Science Education
9. Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share
10. Protein Clumps May Appear Years Before Memory Problems
11. Obama Puts Politics Before Principle in Abortion Coverage, Says Religious Coalition for Reproductive Choice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: